European Patent Office

T 0296/93 (HBV antigen production) vom 28.07.1994

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:1994:T029693.19940728
Datum der Entscheidung
28. Juli 1994
Aktenzeichen
T 0296/93
Antrag auf Überprüfung von
-
Anmeldenummer
85201908.2
IPC-Klasse
C12N 15/51
Verfahrenssprache
Englisch
Verteilung
Im Amtsblatt des EPA veröffentlicht (A)
Amtsblattfassungen
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
Recombinant DNA molecules and their method of production
Name des Antragstellers
BIOGEN
Name des Einsprechenden
Murex Technologies
Institut Pasteur Etablissement public
Immuno Aktiengesellschaft
Hexal-Biochtech GmbH
Medeva PLC
Kammer
3.3.04
Leitsatz

The applicable starting point for calculating the three month period for intervention under Article 105(1) EPC is always the date of the institution of the first court action. Where a court action for infringement was first brought by a patentee against an alleged infringer, Article 105(1) EPC first sentence applies, even though the latter later instituted a court action seeking a declaration of non-infringement under Article 105(1) EPC second sentence, with regard to the same patent.

Schlagwörter
Admissibility of intervention of assumed infringer (no) - too late
Entitlement to priority (yes) - same invention
Citability of prior art document (no)
Novelty (yes)
Inventive step (yes)
Enlarged Board - referral (no)
Orientierungssatz
-

ORDER

For these reasons it is decided that:

1. The intervention is rejected as inadmissible.

2. The decision under appeal is set aside.

3. The case is remitted to the first instance with the order to maintain the patent on the basis of Claims 1 to 23 (non-AT States) and Claims 1 to 11 (AT) as filed in the oral proceedings.

4. The request for referral of a question to the Enlarged Board of Appeal is refused.